• FDA approves AstraZeneca-Amgen’s Tezspire for severe asthma treatment Pharmaceutical-Technology
    December 21, 2021
    The US Food and Drug Administration (FDA) has granted approval to AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) as an add-on maintenance therapy for severe asthma in adults and paediatric individuals of the age 12 years and above.
PharmaSources Customer Service